Psilocybin rewired prefrontal circuits in mice — but only for one specific type of cognitive failure

Key Findings

🏠 Where You Take Psilocybin Shapes What It Does to Your Brain

• In a 15-person human study, participants who took psilocybin in a therapeutic-like room reported more intense experiences and longer-lasting psychological benefits than those dosed inside an MRI scanner.
• The therapeutic-room group also showed greater increases in a marker of synaptic density in the frontal cortex and hippocampus — though the overall group result wasn't statistically significant.

🐭 Schizophrenia-Linked Gene Deletion Amplifies Psilocybin's Acute Effects — and Unlocks a Long-Term Benefit in Females

• In mice engineered to lack a glutamate receptor linked to schizophrenia risk, psilocybin triggered hyperactivity and amplified behavioral responses that were absent in normal mice.
• Nine days after a single dose, female knockout mice showed normalized sensorimotor gating — a deficit common in schizophrenia — while males did not, pointing to a sex-dependent long-term effect.

🌿 An Ayahuasca-Inspired Formula Reduced Embarrassment and Shame in a Placebo-Controlled Trial

• A randomized trial in healthy volunteers tested a combination of DMT and harmine — the two core active compounds in ayahuasca — on social self-evaluation tasks designed to provoke embarrassment and shame.
• The formulation reduced negative self-referential emotions compared to placebo, targeting a dimension of psychological distress that standard antidepressants often don't reach.

👁️ DMT's 'Entity Encounters' Follow a Predictable Build — Not a Random Hallucination

• Micro-phenomenological interviews with 23 participants who received intravenous DMT during simultaneous brain imaging revealed a consistent sequence: bodily effects came first, then visual and auditory ones, then encounters with perceived presences.
• Perceived presences only emerged after multisensory integration and a sense of three-dimensional space had already developed — suggesting a hierarchical construction process rather than an unpredictable perceptual event.

⚖️ UK Regulators Are Being Asked Why Assisted-Suicide Drugs Get a Fast Lane That Psychedelics Don't

• Two editorials in the British Journal of Psychiatry flagged a regulatory inconsistency: drugs proposed for assisted suicide in the UK may bypass standard evidence requirements, while psychedelics with a growing clinical evidence base remain tightly restricted.
• One editorial argued psychedelic therapy — which has shown reductions in end-of-life distress — deserves evaluation as an alternative before assisted suicide is institutionalized.

💊 GHB's Path From Schedule I to Clinic Offers a Regulatory Roadmap for Psychedelics

• A JAMA Psychiatry viewpoint examined how sodium oxybate — derived from gamma-hydroxybutyrate, a Schedule I substance — navigated regulatory approval and reached clinical use.
• The authors argue this precedent illustrates a viable pathway for psychedelics and other controlled substances currently stuck behind scheduling barriers, without requiring new legislation.